Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?

Yes. While some uncommon EGFR exon 19 deletions appear to be resistant to first and third-generation EGFR TKIs (e.g., L747P variant with higher IC50 requirements preclinically and associated with worse response/survival in case analyses), EGFR E746_S752delinsV appears to respond well to EGFR TKIs (W...